Advocates are celebrating a recent U.S. federal decision by HHS recommending that all newborns be screened for Duchenne ...

As 2025 draws to a close, columnist Shalom Lim looks back at the highs and lows he's experienced this year while living with ...

The FDA has granted rare pediatric disease designation to (Z)-Endoxifen as a potential treatment for Duchenne muscular ...

During this season of hope, columnist Robin Stemple shares his wishes for both the disability community and himself.

Experimental therapy deramiocel outperformed a placebo at improving measures of arm and heart health in people with DMD in a ...

Columnist Patrick Moeschen argues that we all should focus more on finding the right words to accurately describe living with ...

Navigating the holidays creates some logistical problems for my family. It’s not because there are nine of us. We might be a big family, but if we can all fit in our average-sized, ranch-style home, ...

Dyne Therapeutics, citing trial data, said it will ask the FDA to approve DYNE-251, its therapy for DMD amenable to exon 51 skipping.

Dyne Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) to approve DYNE-251, its exon-skipping therapy for people with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...